MIPS Molecular Imaging Program at Stanford

2015 MIPS Molecular Imaging Seminar Series

Calendars and Scheduling

Use the links below to view event calendars and the availability and schedules of rooms.

Seminar 5:30 − 6:15 pm
Discussion 6:15 − 6:30 pm
Reception 6:30 − 7:00 pm
Li Ka Shing Center, Rm. LK130
Stanford University Campus

You will need the free QuickTime Player QuickTime logo
to view the webcast of lectures.

Invited Speakers
January 9, 2015 Robert Grubbs, PhD
February 3, 2015 Hyunsuk Shim, PhD - View Webcast
March 5, 2015 Garry Nolan, PhD - View Webcast
April 2, 2015 Mikhail G. Shapiro, PhD
May 7, 2015 Zahi A. Fayad, PhD, FAHA, FACC, FISMRMD - View Webcast
June 2015 (no seminar) Summer Hiatus
July 2015 (no seminar) Summer Hiatus
August 2015 (no seminar) Summer Hiatus
September 10, 2015 Jae Sung Lee, PhD
October 1, 2015 Erik M Shapiro, PhD
December 3, 2015 Neil Vasdev, PhD


Jan 9, 2015

Photo of Robert Grubbs, PhD
Robert Grubbs, PhD

Victor and Elizabeth Atkins Professor of Chemistry
Adventures in the Development of Materials for Clinical Applications

The Grubbs group discovers new catalysts and studies their fundamental chemistry and applications. Catalysts facilitate the transformation of organic molecules and are used widely in industry and academia for the preparation of important organic compounds and polymers. A family of catalysts for the interconversion of olefins, the olefin metathesis reaction has been discovered in the Grubbs laboratory. In addition to their broad usage in academic research, these catalysts are now used commercially to prepare new pharmaceuticals, composites for structural applications and for the conversion of biorenewable carbon sources into fuels and commodity chemicals. Catalysts for other useful transformations are also being developed and studied in detail.

His more recent awards have included the Nobel Prize in Chemistry (2005), Benjamin Franklin Medal in Chemistry (2000), Pauling Award Medal 2003), Havinga Medal (2006) (Leiden University), Golden Plate Award (2006) (Academy of Achievement), Gold Medal of the American Institute of Chemists (2010) 8 ACS Awards including: Polymer Chemistry (1995), Arthur C. Cope Award (2002), Award for Creative Invention (2009), ACS Roger Adams Award in Organic Chemistry (2011), Giulio Natta Award for Chemistry (2014). He was elected to the National Academy of Sciences (1989), Fellow of the American Academy of Arts and Sciences (1994), the Honorary Fellowship of the Royal Society of Chemistry (2006), Fellows of the American Chemical Society (2009), ACS Polymer Division Fellow (2010), Gold Medal of the American Institute of Chemists, Chemical Heritage Foundation (2010). He has been awarded many honorary degrees, the most recent being an Honorary Degree of DSc from University of Warwick, Coventry (2010), Honors Causa Doctrorate, Univerdidad de Huelva, Spain (2012), Commencement Speaker at KAUST, Jeddah, SA (2012), and RWTH Aachen University Honorary Doctorate (Dr.rer.nat.h.c.) (2013). He has 580+ publications and 129+ patents based on his research.
Feb 3, 2015

Photo of Hyunsuk Shim
Hyunsuk Shim, PhD

Department of Radiology and Imaging Sciences
Emory University

View Webcast
Emory QIN: The use of high resolution volumetric MR spectroscopic imaging in the management of glioblastoma

The objective of Emory QIN project is to establish quantitative, high resolution, volumetric magnetic resonance spectroscopic imaging (MRSI) as a primary biomarker for predicting and monitoring treatment response in human brain tumors. The technology will be applied to a trial of a promising histone deacetylase (HDAC) inhibitor, in combination with standard therapy in patients with glioblastoma (GBM). In addition, we apply our technology in surgical planning as well as radiation planning for GBM patients. GBM resection using neuronavigation based on contrast-enhanced MRI (CE-MRI) results in a high rate of local recurrence, as infiltrating tumor cells extend beyond areas of contrast enhancement. Integrating metabolic maps from MRSI into neuronavigation may identify high-risk tumor infiltration zones outside of CE-MRI for surgery. While CE-MRI images tumor vasculature, MRSI directly images tumor cells via their altered metabolism. Coupling MRSI with fluorescence-guided surgery (FGS) using 5-aminolevulinic acid (5-ALA) may provide a means to enhance the degree of tumor resection further.
Mar 5, 2015

Photo of Garry Nolan, PhD
Garry Nolan, PhD

Rachford and Carlota A. Harris Professor
Dir, NHLBI Proteomics Center for Systems Immunology
Baxter Lab for Stem Cell Bio
Stanford School of Medicine View Webcast
Next Steps in High Parameter Imaging and Single Cell Analysis

Dr. Nolan's laboratory works on a number of single cell analysis and imaging approaches.  I will discuss recent advances in multiparameter mass based detection of cellular components (proteins, mRNA, protein-DNA contacts) in flow cytometric and histology based platforms using CyTOF and MIBI.  I will detail research (iPS cells) and clinical applications (immune based detection of trauma & recovery, AML) as well as computational approaches to analyze the data produced on these and other high parameter platforms we are developing.
Apr 3, 2015

Photo of Mikhail Shapiro
Mikhail G. Shapiro, PhD

Assist Prof, Chem Eng
Biomolecular Engineering for Non-invasive Imaging of Biological Function

Many important biological processes – ranging from simple metabolism to complex cognition – take place deep inside living organisms, yet our ability to study them in this context is very limited. Technologies such as fluorescent proteins and optogenetics enable exquisitely precise imaging and control of cellular function in small, translucent specimens using visible light, but are limited by the poor penetration of such light into larger tissues. In contrast, most non-invasive technologies such as magnetic resonance imaging (MRI) and ultrasound – while based on energy forms that penetrate tissue effectively – lack the needed molecular precision. Our work attempts to bridge this gap by engineering new molecular technologies that connect penetrant energy to specific aspects of cellular function in vivo. In this talk, I will describe molecular reporters for non-invasive imaging using MRI and ultrasound developed by adapting and engineering naturally occurring proteins. These proteins have physical properties, such as paramagnetism or self-assembly into hollow nanostructures, that allow them to be sensitively detected with MRI and ultrasound. By engineering them at the genetic level, we have adapted these natural constructs into non-invasive molecular reporters of biological processes ranging from gene expression to chemical neurotransmission.
May 7, 2015

Photo of Zahi Fayad
Zahi A. Fayad, PhD, FAHA, FACC, FISMRM

Prof, Rad & Med (Card)
Dir, Translational and Molecular Institute
Vice chair for Research, Rad
Mount Sinai, New York, NY
View Webcast

Imaging and Nanomedicine in Inflammatory Atherosclerosis

Atherosclerosis is a chronic progressive disease, affecting the medium and large arteries, in which lipid-triggered inflammation plays a pivotal role. The major clinical manifestations of atherosclerosis are coronary artery disease (CAD), leading to acute myocardial infarction (MI) and sudden cardiac death; cerebrovascular disease, leading to stroke; and peripheral arterial disease, leading to ischemic limbs and viscera. These complications of atherosclerosis are leading causes of death worldwide. Despite progress in medical and revascularization therapies for atherothrombotic disease, the incidence of MI and stroke remain high under the current standard of care, and the past decade has generated few new medical therapies to prevent atherosclerosis-induced events. Similarly, current diagnostic approaches to atherosclerosis do not accurately identify those individuals who will suffer an ischemic complication. The field of atherosclerosis is therefore ripe for reengineering in both the therapeutic and diagnostic arenas. Research into the process of atheroma lesion development and maturation has implicated many immune cells including lymphocytes, dendritic cells, and neutrophils. The most numerous cells in atherosclerotic plaque are macrophages, which are leukocytes that are central to the innate immunity. Because they play a major role in instigating plaque development and complication—both of which are inflammation-related disease processes—leukocytes are promising targets for more effective atherosclerosis treatments. However, the complexity of the immune system and its role as a defensive force against infection require novel tools to very precisely identify and treat the inflammatory cells that promote atherosclerosis. Biomedical engineering offers unique possibilities for diagnosing and treating atherosclerotic plaque inflammation. Thus, interfacing engineering with immunology will be essential to meaningful advances in disease management.

Sept 10, 2015
Munzer Auditorium

Photo of Jae Sung Lee

Jae Sung Lee, PhD

Prof, Nuclear Medicine / Biomedical Sciences
Seoul National University College of Medicine
Seoul, Korea


Development of Advanced Hybrid Biomedical Imaging Systems and Their Applications


Prof. Jae Sung Lee’s laboratory primarily works on the development of advanced technologies for hybrid biomedical imaging systems, such as PET/MRI and PET/CT. For the last couple of years, we have developed a silicon photomultiplier (SiPM)-based MRI-compatible preclinical PET system that has a relatively long axial field-of-view and high spatial resolution optimized for small animal imaging. In this talk, I will present this system and simultaneous PET/MRI studies in mice to demonstrate the feasibility of the developed system for evaluating the biochemical and cellular changes in a brain tumor model and facilitating the development of new multimodal imaging probes. In addition, we have focused on the development of advanced time-of-flight (TOF) PET system that is based on position-sensitive high quantum efficiency (HQE) photomultiplier tubes, yielding better timing resolution with smaller cross sectional (3 x 3 x 20 mm) lutetium based scintillation crystals than current commercial PET systems. The results of various phantom studies to demonstrate the superb timing performance of this system will be presented.

Oct 1, 2015
Munzer Auditorium

Photo of Erik Shapiro

Erik M Shapiro, PhD

Associate Professor and Associate Chair for Research
Department of Radiology
Michigan State University


Molecular and cellular imaging with MRI and CT:A tale of two modalities


Molecular imaging by MRI is a well-established scientific field. Our contribution to this field has been the development of MRI-based cell tracking methodologies aimed at detecting single cells in vivo. This has been enabled by three key developments: 1) Judicious choice and optimization of magnetic cell labeling particles, 2) Appropriate and innovative animal models, and 3) Sophisticated image analysis tools. As opposed to MRI, molecular imaging by CT is fairly unexplored. The main reason for this has been the dismal sensitivity of CT for x-ray dense contrast materials, minimally in the 10’s of millimolar. Despite this, we have developed multi-color molecular CT approaches for targeted CT nanomaterials and tissue engineered constructs. This has been chiefly driven by: 1) Innovations in nanocrystals and polymer embedded nanoparticles, 2) Biomaterial fabrication and 3) Multi-energy acquisition and data analysis schemes.

Dec 3, 2015
Munzer Auditorium

Photo of Neil Vasdev

Neil Vasdev, PhD

Director of Radiochemistry, Massachusetts General Hospital
Associate Professor, Harvard Medical School

New radiopharmaceuticals, targets and radiochemical methods for PET neuroimaging


This presentation will focus on some non-traditional approaches to prepare PET radiopharmaceuticals for new targets to image the human brain, and aims to show the intricacies of developing PET radiopharmaceuticals from "bench to bedside". Specifically, cutting-edge approaches and technologies for imaging the dopaminergic pathway with PET, as well as our recent work to expand beyond the "amyloid cascade hypothesis" of Alzheimer's disease, including tauopathies, will be presented. Several of the neuroimaging agents have also been applied as oncology probes. The intricacies of transitioning labeled compounds to PET radiopharmaceuticals and our aspiration to work towards the ultimate, albeit impossible, goal in the field: to radiolabel virtually any compound for PET will be raised as points for discussion.

Sponsored by: Molecular Imaging Program at Stanford (MIPS) (mips.stanford.edu);
Host: Director, Sanjiv Sam Gambhir, MD, PhD (sgambhir@stanford.edu)

If you would like to be included on the MIPS email distribution list for weekly meeting reminders, contact Susan Singh.

Footer Links: